Bunkerhill ECG-EF vs EchoNext

Direct competitors — feature-level head-to-head below. Comparability 85/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Bunkerhill ECG-EF

by BunkerHill Health

EchoNext

by Pathway Labs

AI Verdict

Both Bunkerhill ECG-EF and EchoNext are FDA-cleared AI tools that analyze standard 12-lead ECGs to detect cardiac conditions, making them direct competitors. Bunkerhill ECG-EF specifically focuses on identifying reduced left ventricular ejection fraction for heart failure risk, while EchoNext offers a broader detection of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

Choose Bunkerhill ECG-EF if…

Choose Bunkerhill ECG-EF if your primary goal is the early identification of patients at risk for heart failure by specifically detecting reduced left ventricular ejection fraction (LVEF ≤ 40%) from routine 12-lead ECGs. This tool is ideal for integrating into existing EHRs and clinical archives to support automated workflows for screening and flagging high-risk patients for further evaluation.

View Bunkerhill ECG-EF →

Choose EchoNext if…

Choose EchoNext if you need a comprehensive AI tool to detect a broader range of hidden structural heart diseases, including various forms of heart failure, valve disease, and pulmonary hypertension, from standard ECGs. This tool is particularly well-suited for broad access across different clinical settings, from major hospitals to community practices, and integrates with clinical decision support platforms like OpenEvidence.

View EchoNext →

When choosing between Bunkerhill ECG-EF and EchoNext, physicians should consider their primary diagnostic focus and operational needs. Bunkerhill ECG-EF excels at the specific and early identification of reduced left ventricular ejection fraction (LVEF ≤ 40%) from routine 12-lead ECGs, making it ideal for practices heavily focused on heart failure risk stratification. Its integration with EHRs and clinical archives streamlines workflows for this particular condition.

In contrast, EchoNext offers a broader diagnostic scope, analyzing standard ECGs to detect a range of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension. The key practical difference lies in their breadth of analysis: Bunkerhill ECG-EF provides a targeted assessment for LVEF, while EchoNext offers a more comprehensive screening for multiple cardiac conditions. Physicians whose primary concern is early and specific LVEF detection may find Bunkerhill ECG-EF more tailored to their needs. Conversely, practices seeking a single AI tool to screen for a wider array of structural heart diseases, beyond just LVEF, might prefer EchoNext for its broader diagnostic utility. EchoNext’s tiered pricing structure and availability through the OpenEvidence platform may also appeal to practices with varying budget and integration preferences.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Bunkerhill ECG-EF	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Integrates seamlessly with EHRs and clinical archives.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both tools integrate with existing EHRs and ECG management systems, suggesting a similar level of ease of integration into clinical workflows. Neither tool provides specific details on their user interface or direct user experience, making it difficult to differentiate them further on this dimension.

Clinical Value

EchoNext

EchoNext demonstrates broader clinical utility by detecting a wider range of structural heart diseases, including heart failure, valve disease, and pulmonary hypertension, compared to Bunkerhill ECG-EF's focus on reduced left ventricular ejection fraction. EchoNext has also shown superior accuracy in head-to-head comparisons with cardiologists and has been credited with directly leading to a heart transplant in a peer-reviewed case.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, with details on implementation fees and annual discounts, allowing for clearer budget planning. Bunkerhill ECG-EF requires contacting for pricing, which offers less transparency upfront. Additionally, EchoNext's broader detection capabilities may offer more comprehensive value for its cost.

Enterprise Readiness

Bunkerhill ECG-EF

Bunkerhill ECG-EF is part of the broader Carebricks platform, which is designed for generative AI for clinical reasoning and action, enabling health systems to create tailored, AI-powered workflows and automate next steps. This indicates a more robust enterprise-level platform capability beyond just the ECG analysis.

Innovation

EchoNext

EchoNext stands out for its ability to detect a wider array of hidden structural heart diseases from ECGs, including conditions not previously detectable by ECG, and has been recognized as the world's first FDA-approved AI detection tool for this broad scope. This represents a more significant advancement in diagnostic capabilities compared to Bunkerhill ECG-EF's focus on LVEF.

Support & Docs

Tie

Both companies are FDA-cleared and HIPAA compliant, implying a baseline level of regulatory documentation and support. However, neither product's description or available web search results provide specific details about their customer support channels, documentation quality, or training resources, making a definitive comparison impossible.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Bunkerhill ECG-EF	EchoNext
Tool Name	Bunkerhill ECG-EF	EchoNext
Company	BunkerHill Health	Pathway Labs
Description	FDA-cleared artificial intelligence algorithm that detects reduced left ventricular ejection fraction (LVEF u2264 40%) from routine 12-lead electrocardiograms (ECGs), aiding in the early identification of patients at risk for heart failure.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Detections	Reduced Left Ventricular Ejection Fraction (LVEF u2264 40%)	Hidden structural heart disease, heart failure, valve disease, pulmonary hypertension

Videos

Demos, reviews, and walkthroughs featuring Bunkerhill ECG-EF and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

Bunkerhill ECG-EF integrates seamlessly with EHRs and clinical archives as part of the Carebricks platform, which is designed to automate clinical workflows, including identifying findings, prioritizing patients for follow-up, and automating care coordination. EchoNext is available through the OpenEvidence clinical decision support platform, which is used by a large number of U.S. physicians and integrates with EHRs through HL7v2 order and results workflows, single sign-on (SSO), and SMART on FHIR.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

Bunkerhill ECG-EF achieved a sensitivity of 82.66% and a specificity of 83.20% for detecting reduced LVEF (u2264 40%). EchoNext demonstrated higher accuracy (77%) in identifying structural heart problems from ECGs compared to cardiologists (64%) in a study. It was trained on over 700,000 paired ECG and echocardiogram records and has shown robust performance across diverse patient demographics and clinical contexts.

Which specific cardiac specialties are these tools best suited for, beyond general cardiology?

Bunkerhill ECG-EF is particularly suited for Cardiology, Emergency Medicine, and Internal Medicine, aiding in the early identification of patients at risk for heart failure. EchoNext is designed for Cardiology, Family Medicine, Hospital Medicine, and Internal Medicine, focusing on detecting hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

What is the anticipated learning curve for physicians to effectively use these AI tools?

While specific learning curve details are not provided, both tools are designed to integrate into existing workflows. Bunkerhill ECG-EF aims to reduce manual workload by automating next steps, suggesting a focus on integrating AI insights into current practices rather than extensive new procedures. EchoNext is available on the OpenEvidence platform, which is widely used by physicians, implying an accessible integration into familiar clinical decision support environments.

What kind of customer support and resources are available for implementation and ongoing use?

Bunkerhill Health's Carebricks platform offers tailored AI-powered workflows and aims to support clinicians in ensuring patients receive the right care, suggesting comprehensive support for implementation and ongoing use. Pathway Labs, with its partnership with OpenEvidence, aims to expand access to EchoNext's screening tool and support its deployment across health systems, indicating resources for integration and utilization.

What audit-trail features do these tools offer to ensure transparency and accountability in AI-assisted diagnoses?

While specific audit-trail features are not detailed, Bunkerhill's Carebricks platform emphasizes clinical reasoning and action, which often necessitates transparent tracking of AI-driven insights and automated actions. EchoNext, as part of a clinical decision support platform, would likely incorporate features to document AI-assisted analyses to support clinical decision-making and accountability.

How do these tools handle multi-site rollouts and ensure consistent performance across different clinical environments?

Bunkerhill ECG-EF is available through the MyoVista Insights platform, which aims to make the algorithm accessible to healthcare facilities of every size, from large integrated health systems to community practices, suggesting considerations for broad deployment. EchoNext has demonstrated consistent performance across diverse patient demographics, clinical contexts, and numerous hospitals in validation studies, indicating its suitability for multi-site rollouts.